Evaluating In House HSV PCR Capabilities, A Cost Benefit Analysis
59th Medical Wing San Antonio United States
Pagination or Media Count:
Neonatal HSV occurs in approximately 1 out of 3,200 to 10,000 live births, with 1500 cases reported annually and accounting for 0.2 of neonatal hospitalizations and 0.6 of In-hospital neonatal deaths in the US. HSV disease carries not only significant medical and financial costs, but considerable diagnostic challenges. The advent of the HSV PCR modality offers alleviation to the associated costs and diagnostic dilemma. Previous studies have cited relative decrease in median lab turnaround time when implementing real-time PCR capabilities, resulting In quantifiable decreased hospital LOS for pediatric patients and institutional lab cost savings. In addition, significant iatrogenic complications are associated with parenteral Acyclovir therapy including nausea and vomiting, hepatic and renal injury, and local inflammation to injection sites.
- Medicine and Medical Research